Integra Connect’s Post

The PI3K pathway is important for normal functions in the body, but it can also play a key role in breast cancer. We’ll hear from Komen Scholar Carlos Arteaga, M.D. medical oncologist Komal Jhaveri M.D. and Komen Advocate in Science Thelma Brown about the challenges of targeting this pathway and how new research is ushering in the next generation of PI3K inhibitors to treat breast cancer. Watch and read here: https://bit.ly/47s1x9V

From presidential sessions to pragmatic trials, #ESMO25 offered no shortage of insights. One standout was the LenCabo study, comparing lenvatinib + everolimus with cabozantinib after IO therapy and showing a strong PFS signal. In Episode 32, Dr. Aly-Khan Lalani, MD, FRCPC dives into the data, calling it “a tease for what we’d want to see in a future trial.” Catch this discussion, and the full ESMO - European Society for Medical Oncology 2025 Recap Series covering bladder, prostate, and kidney cancer, at theviewongu.com #Podcast #Cancer #GUCancer #KidneyCancer #BladderCancer #GUCancers #GUTreatments #ClinicalOncology Christopher Wallis

In our most recent #TalkClinicalTrials article, Rethink Breast Cancer highlights the need to improve access, awareness, and inclusion for people living with metastatic breast cancer in clinical research. Their statement calls for meaningful changes to ensure trials better reflect the realities and priorities of those affected. We’re also excited to welcome Margaret Loniewska, PhD, one of the statement’s authors, to #CTOConf2025! She’ll be joining the panel “Trials in Real Life: Not Black and White, But Grey All Over” to share her perspective on what it means to make trials more patient-centred in practice. 📖 Read the full article: https://bit.ly/4nRXdaJ Learn more about the conference: https://t.co/U6jzuUcrYJ

Lutetium-PSMA stole the spotlight with its own presidential at #ESMO2025! 🌟The highly publicized PSMAddition trial presented by Scott Tagawa is broken down by your hosts Dr. Aly-Khan Lalani, MD, FRCPC and Dr. Christopher Wallis in Episode 31. Tune in to hear their expert insights! Discover how these results could expand the theranostic paradigm and impact men with metastatic castration-sensitive prostate cancer. Watch or listen now: https://theviewongu.com #Podcast #Cancer #GUCancer #KidneyCancer #BladderCancer #GUCancers #GUTreatments #ClinicalOncology ESMO - European Society for Medical Oncology

CDK4/6 inhibitors were recently approved for adjuvant treatment of high-risk patients with ER-positive early breast cancer in Denmark. But what does it really look like for our patients? Is there a need for these therapies? If you want to know too, check out our new research paper published this week. Thank you for publishing our results, Acta Oncologica 🙏 Link: https://lnkd.in/dMJ86fY6 (PDF link to full paper at the bottom if mobile version) Tobias Berg, Maj-Britt Jensen, Ann Knoop 🌟

Blinded independent central review (BICR) enhances the objectivity and regulatory credibility of oncology trial endpoints by minimizing bias and standardizing radiographic assessments. But, as Hélène Cauwel and Stéphanie Rondeau discuss, its implementation introduces some key challenges. Read the post to learn more: https://hubs.ly/Q03R2tqL0 #oncology #cancer #BICR #clinicaltrials

As presented at #ESMO25, neoadjuvant trastuzumab deruxtecan plus trastuzumab, pertuzumab, and docetaxel significantly improved pathologic complete response rates and showed a more favorable safety profile compared to standard anthracycline-based therapy in patients with high-risk, HER2-positive early breast cancer. Learn more: https://lnkd.in/ejMz76vZ

In the past decade, breast cancer treatments have exponentially improved. Thanks to clinical trials and the patients who join them, treatments today are more personalized, less invasive, and more effective than ever. Every breakthrough—from targeted therapies to immunotherapy—started with a clinical trial. If you or a loved one is facing breast cancer, exploring clinical trials can be an empowering step. Together, patients and researchers are turning today’s trials into tomorrow’s triumphs. Read the full blog here: https://lnkd.in/e82E-yFn #BreastCancerAwareness #ClinicalResearch #ClinicalTrials

We were thrilled to see two posters featuring TILT Biotherapeutics data presented by our collaborators from the University of Helsinki — Elise Jirovec and Nea Ojala.Their work continues to deepen the understanding of TILT’s oncolytic immunotherapy platform and its potential in advancing cancer treatment. Check the posters from Tiltbio´s webpage: https://lnkd.in/eFgf2C93 The momentum doesn’t stop here! More exciting TILT Science will be shared later this year at the Society for Melanoma Research Congress, SITC, and ESMO Immuno-Oncology. #OncolyticViruses #Immunotherapy #CancerResearch #Collaboration #TILTTherapy

UCLA researchers have developed a novel therapy that could fundamentally change the treatment plan for triple-negative breast cancer, one of the most aggressive cancers. “Patients with triple-negative breast cancer have been waiting far too long for better treatment options,” said senior author Dr. Lili Yang. “To finally have a therapy that shows superior cancer-fighting ability — and to be just one step away from clinical testing — is incredibly exciting.” #ResearchPowersProgress ➡️ https://bit.ly/47jLomR